基础医学与临床 ›› 2024, Vol. 44 ›› Issue (6): 763-771.doi: 10.16352/j.issn.1001-6325.2024.06.0763

• 研究论文 • 上一篇    下一篇

靶向BCMA的CAR-γδT细胞抗多发性骨髓瘤的疗效

李盈辉1, 许依1,2, 张建民1,2, 陈慧1,2*, 何维1*   

  1. 1.中国医学科学院基础医学研究所 北京协和医学院基础医学院 免疫学系 T细胞与免疫治疗重点实验室重大疾病共性机制研究全国重点实验室,北京 100005;
    2.常州西太湖细胞治疗前沿技术研究院,江苏 常州 213000
  • 收稿日期:2024-03-19 修回日期:2024-04-18 出版日期:2024-06-05 发布日期:2024-05-24
  • 通讯作者: *chenhui@ibms.pumc.edu.cn; hewei@ngd.org.cn
  • 基金资助:
    中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-035);国家自然科学基金(32270915,U20A20374)

Therapeutic effect of CAR-γδT cells targeting at BCMA in multiple myeloma

LI Yinghui1, XU Yi1,2, ZHANG Jianmin1,2, CHEN Hui1,2*, HE Wei1*   

  1. 1. Department of Immunology, CAMS Key Laboratory for T Cell and Immunotherapy, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005;
    2. Changzhou Xitaihu Institute for Frontier Technology of Cell Therapy, Changzhou 213000, China
  • Received:2024-03-19 Revised:2024-04-18 Online:2024-06-05 Published:2024-05-24
  • Contact: *chenhui@ibms.pumc.edu.cn; hewei@ngd.org.cn

摘要: 目的 构建靶向B细胞成熟抗原(BCMA)的嵌合抗原受体γδT细胞(BCMA CAR-γδT),在体外初步评价其抗多发性骨髓瘤的疗效。方法 构建包含BCMA单链抗体序列的三代CAR分子的慢病毒载体,瞬时转染293T细胞,荧光显微镜和Western blot验证外源基因的表达情况;包装慢病毒,用流式细胞术测定病毒滴度;分别感染人外周血αβT细胞和γδT细胞,检测感染效率; LDH法检测BCMA CAR-γδT细胞对人多发性骨髓瘤细胞系的体外细胞毒活性,并用Incucyte实时细胞分析系统比较BCMA CAR-γδT细胞与BCMA CAR-T细胞的细胞毒活性差异。结果 将BCMA-CAR慢病毒载体转入293T细胞24 h后,荧光显微镜观察到外源ZsGreen的表达;Western blot检测CD3ζ证明BCMA-CAR能顺利表达。慢病毒包装后,收集感染上清浓缩,测得病毒滴度为2.23×108 Tu/mL。用MOI=5感染人外周血αβT细胞与γδT细胞,流式检测结果显示αβT细胞感染效率为59.18%±2.56%,γδT细胞感染效率为48.15%±9.86%。LDH杀伤实验结果显示,CAR-γδT细胞对BCMA高表达的人骨髓瘤细胞系MM1.S、H929和过表达BCMA的K562细胞的细胞毒活性较空载体对照γδT细胞显著增强(P<0.001),而对BCMA表达阴性的细胞系无差异;活细胞时程分析系统结果显示,BCMA CAR-γδT细胞与BCMA CAR-αβT细胞在体外对H929的细胞毒活性均显著优于其空载体对照细胞,且均对BCMA表达阴性的细胞系的细胞毒活性无差异。结论 BCMA CAR-γδT细胞在体外显示出明显增强的靶向BCMA的细胞毒活性,有望作为新型同种异体γδT细胞产品,用于多发性骨髓瘤的细胞过继免疫治疗。

关键词: B细胞成熟抗原, 多发性骨髓瘤, 嵌合抗原受体, γδT细胞

Abstract: Objective To construct chimeric antigen receptors modified γδT cells targeting at BCMA (BCMA CAR-γδT) and to evaluate its efficacy of anti-multiple myeloma in vitro. Methods Lentiviral vectors containing BCMA single-chain variable fragment were constructed and transiently transfected into 293T cells. The expression of foreign genes was verified by fluorescence microscopy and Western blot; the lentivirus was packaged and the virus titer was determined by flow cytometry. Human peripheral blood αβT cells were infected and γδT cells were examined for its infection efficiency; LDH release method was used to detect the cytotoxic activity of BCMA CAR-γδT cells against human multiple myeloma cell lines in vitro, and the difference of cytotoxic activity between CAR-γδT cells and CAR-αβT cells was compared by Incucyte S3 Live-Cell Analysis Instrument. Results Twenty-four hours after BCMA-CAR lentiviral vector was transferred into 293T cells, the expression of exogenous ZsGreen was microscopied by fluorescence microscope; CD3ζ was detected by Western blot, which showed that BCMA-CAR could be successfully expressed. The lentivirus was packaged, collected and concentrated(virus titer of 2.23×108 Tu/mL). Infected αβT cells and γδT cells from human peripheral blood in MOI=5, and the results of flow cytometry showed that infection efficiency of αβT cells was 59.18%±2.56%, γδT cells was 48.15±9.86%. The cytotoxic activity of CAR-γδT cells against human myeloma cell lines MM1.S, H929 with high expression of BCMA and K562 cells with over-expression of BCMA was higher than that of empty vector control γδ T cells,which were significantly enhanced (P<0.001), but there was no difference in cell lines negative for BCMA expression; Live-Cell Analysis Instrument results showed that the cytotoxic activity of BCMA CAR-γδT cells and BCMA CAR-αβT cells against H929 in vitro was significantly better than their vector control cells. There was no difference in the cytotoxic activities of BCMA CAR-γδT cells as compared with against BCMA negative cell lines, and so do BCMA CAR-T cells. Conclusions Cytotoxic activity of BCMA CAR-γδT targeting at BCMA in vitro was significantly enhanced ,which is expected to serve as a novel allogeneic γδT cell product for cell adoptive immunotherapy of multiple myeloma.

Key words: B-cell maturation antigen, multiple myeloma, chimeric antigen receptors, γδT cells

中图分类号: